The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
|Expert Interviews|April 18, 2022
Expert Interview: Pfizer/BioNTech Immune Response in Pediatric Clinical Trials
Author(s)Lois Levine, MA
Pfizer/BioNTech announce positive results for a third dose of their COVID-19 vaccine for children.
Advertisement
Grant Paulsen, MD, assistant professor, Division of Infectious Disease, Department of Pediatrics, Cincinnati Children's Hospital Medical Center in Ohio, and primary investigator for the hospital's clinical trial for a third dose (booster) for the Pfizer/BioNTech vaccine for COVID-19, discusses what the data might mean for children aged 5 to 11 years.
Advertisement
Related to this article
The expert explains 2025-1016 flu, COVID-19, and RSV vaccine updates from AAP, ACOG, AAFP, and IDSA, and what changing schedules mean for pharmacists.
A cross-sectional survey links chronic fatigue, cognitive impairment, and menstrual irregularity to COVID-19 vaccination, with rates differing by brand.
A review of hospitalized patients with COVID-19 links female sex, severe acute illness, and intensive care unit admission to higher odds of long COVID.
A population-level analysis finds that age, comorbidity burden, and long-term care residence continue to drive severe outcomes.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Expert Discusses Flu and COVID-19 Vaccine Guidance
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Generic Drug Costs Burdening Patients as Much as Brand Name Options
5